Apredica Acquires Cellumen | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Contract research organization Apredica announced today that it has acquired the intellectual property and related assets of Cellumen for an undisclosed sum.

The acquisition provides Apredica with Cellumen's Cellular Systems Biology and high-content toxicology services and technologies. Specifically, Watertown, Mass.-based Apredica said that the deal will "significantly strengthen" the firm's high-content toxicology offerings.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.